[MAYBANK] QoQ TTM Result on 30-Jun-2015 [#2]

Announcement Date
27-Aug-2015
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2015
Quarter
30-Jun-2015 [#2]
Profit Trend
QoQ- 0.13%
YoY- 2.53%
View:
Show?
TTM Result
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
Revenue 42,554,416 40,556,371 39,165,809 36,716,203 36,539,599 35,712,006 34,319,473 15.40%
PBT 8,840,880 9,151,548 9,206,431 9,049,477 9,145,808 9,111,583 8,982,196 -1.05%
Tax -2,115,600 -2,165,160 -1,937,022 -2,058,389 -2,157,255 -2,200,540 -2,285,194 -5.00%
NP 6,725,280 6,986,388 7,269,409 6,991,088 6,988,553 6,911,043 6,697,002 0.28%
-
NP to SH 6,562,305 6,835,939 7,115,090 6,824,258 6,815,255 6,716,455 6,517,322 0.45%
-
Tax Rate 23.93% 23.66% 21.04% 22.75% 23.59% 24.15% 25.44% -
Total Cost 35,829,136 33,569,983 31,896,400 29,725,115 29,551,046 28,800,963 27,622,471 18.91%
-
Net Worth 61,977,906 61,131,868 59,603,594 56,024,052 55,545,910 52,907,406 49,877,749 15.56%
Dividend
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
Div 5,170,805 5,170,805 5,340,380 5,340,380 5,235,797 5,235,797 4,906,783 3.55%
Div Payout % 78.80% 75.64% 75.06% 78.26% 76.82% 77.95% 75.29% -
Equity
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
Net Worth 61,977,906 61,131,868 59,603,594 56,024,052 55,545,910 52,907,406 49,877,749 15.56%
NOSH 9,745,566 9,672,611 9,528,037 9,454,260 9,306,978 9,307,146 9,126,594 4.46%
Ratio Analysis
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
NP Margin 15.80% 17.23% 18.56% 19.04% 19.13% 19.35% 19.51% -
ROE 10.59% 11.18% 11.94% 12.18% 12.27% 12.69% 13.07% -
Per Share
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
RPS 436.65 419.29 411.06 388.36 392.60 383.71 376.04 10.46%
EPS 67.34 70.67 74.68 72.18 73.23 72.16 71.41 -3.83%
DPS 53.06 53.46 56.05 56.49 56.26 56.26 53.76 -0.86%
NAPS 6.3596 6.3201 6.2556 5.9258 5.9682 5.6846 5.4651 10.62%
Adjusted Per Share Value based on latest NOSH - 9,454,260
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
RPS 352.65 336.09 324.57 304.27 302.81 295.95 284.41 15.40%
EPS 54.38 56.65 58.96 56.55 56.48 55.66 54.01 0.45%
DPS 42.85 42.85 44.26 44.26 43.39 43.39 40.66 3.55%
NAPS 5.1362 5.0661 4.9394 4.6428 4.6031 4.3845 4.1334 15.56%
Price Multiplier on Financial Quarter End Date
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
Date 31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 -
Price 9.02 8.40 8.56 9.14 9.33 9.17 9.96 -
P/RPS 2.07 2.00 2.08 2.35 2.38 2.39 2.65 -15.17%
P/EPS 13.40 11.89 11.46 12.66 12.74 12.71 13.95 -2.64%
EY 7.47 8.41 8.72 7.90 7.85 7.87 7.17 2.76%
DY 5.88 6.36 6.55 6.18 6.03 6.13 5.40 5.83%
P/NAPS 1.42 1.33 1.37 1.54 1.56 1.61 1.82 -15.23%
Price Multiplier on Announcement Date
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
Date 27/05/16 25/02/16 26/11/15 27/08/15 28/05/15 26/02/15 26/11/14 -
Price 8.27 8.64 8.48 8.65 9.11 9.16 9.67 -
P/RPS 1.89 2.06 2.06 2.23 2.32 2.39 2.57 -18.51%
P/EPS 12.28 12.23 11.36 11.98 12.44 12.69 13.54 -6.29%
EY 8.14 8.18 8.81 8.34 8.04 7.88 7.38 6.74%
DY 6.42 6.19 6.61 6.53 6.18 6.14 5.56 10.05%
P/NAPS 1.30 1.37 1.36 1.46 1.53 1.61 1.77 -18.58%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment